Review
Urology & Nephrology
Zoe M. Lipman, Vijayakumar Paramasivam, Gil Yosipovitch, Michael J. Germain
Summary: CKD-aP is a highly prevalent and distressing condition impacting dialysis and nondialysis patients, yet there are limited treatment options and guidelines available. This review evaluated current management and treatment options, including emerging therapies, and proposed new guidelines for managing patients with CKD-aP.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Multidisciplinary Sciences
Christian G. Bolanos, Nhat M. Pham, Robert D. Mair, Timothy W. Meyer, Tammy L. Sirich
Summary: This study used metabolomic analysis to investigate the pruritus symptoms in uremic patients and found no specific solutes associated with pruritus.
Article
Urology & Nephrology
Eriko Kinugasa, Ken Igawa, Hisaki Shimada, Morihiro Kondo, Satoshi Funakoshi, Naoki Imada, Noritomo Itami, Naoki Fukazawa, Ryoko Takubo, Yuichi Kawata, Hiroyuki Murota
Summary: In patients with uremic pruritus, treatment with nemolizumab did not meet the primary efficacy endpoint, but some improvements were observed in the pruritus visual analog scale. Additionally, there were no significant differences in secondary efficacy parameters between treatment groups. Patients with higher serum IL-31 levels tended to have greater reductions in pruritus VAS following nemolizumab treatment.
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2021)
Article
Dermatology
Najmeh Shamspour, Mahin Aflatoonian, Maryam Khalili, Mohsen Seifi, Maryam Mousavi, Jalal Azmandian, Saman Mohammadi, Batoul Khoundabi, Elahenaz Parsimood, Azadeh Mohebbi
Summary: This study aimed to compare the effectiveness of Pregabalin and Ketotifen in treating uremic pruritus in hemodialysis patients. The results showed that Pregabalin had a significantly lower pruritus intensity and better quality of life in the second week of treatment, with fewer side effects compared to Ketotifen.
DERMATOLOGIC THERAPY
(2022)
Article
Hematology
Delong Zhao, Yuanda Wang, Yong Wang, Aili Jiang, Ning Cao, Yani He, Junxia Wang, Zhiyong Guo, Wenhu Liu, Wei Shi, Lirong Hao, Jinyu Li, Wenge Li, Caili Wang, Jianqin Wang, Hongli Lin, Lihua Wang, Hongli Jiang, Guohua Ding, Yun Li, Wenbo Hu, Hua Yue, Jian Liu, Xiaoping Yang, Yibin Yang, Guohui Liu, Hong Li, Yuefei Xiao, Niansong Wang, Gengru Jiang, Guoying Ma, Jie Wang, Ying Li, Rongshan Li, Qian Li, Shiren Sun, Jundong Jiao, Chunsheng Xi, Guangyan Cai, Xuefeng Sun, Xiangmei Chen
Summary: This study investigates the effect of long-term hemoperfusion combined with hemodialysis on middle-molecular-weight toxins and uremic pruritus in maintenance hemodialysis patients. The results show that HP + HD can reduce B2M and PTH levels and improve pruritus independently of the use of high- or low-flux dialyzers.
BLOOD PURIFICATION
(2022)
Article
Urology & Nephrology
Mohamed Mamdouh Elsayed, Iman Ezzat Elgohary, Heidi Hesham Said Abdelhamid, Sherif Aziz Zaki
Summary: This study is a double-blinded, placebo-controlled, multicentric randomized clinical trial that aimed to assess the effect of sertraline on uremic pruritus in hemodialysis patients. The results showed that patients treated with sertraline had a significant improvement in pruritus compared to those who received placebo, suggesting a potential role for sertraline in treating uremic pruritus in hemodialysis patients.
Article
Pharmacology & Pharmacy
Jeffrey G. Stark, Patrick K. Noonan, Robert H. Spencer, Sarbani Bhaduri, Stephen J. O'Connor, Frederique Menzaghi
Summary: This open-label study investigated the pharmacokinetics and disposition of [C-14]difelikefalin in subjects with normal renal function and subjects on hemodialysis. The results showed that subjects on hemodialysis had higher total exposure and longer plasma half-life of difelikefalin.
CLINICAL PHARMACOKINETICS
(2023)
Article
Pharmacology & Pharmacy
Mingming Pan, Guihua Wang, Li Zhou, Yan Xu, Li Yao, Chaoqing Wu, Changlin Mei, Zhanzheng Zhao, Dong Sun, Tianjun Guan, Qinkai Chen, Ming Shi, Hui Xu, Weifang Zeng, Fangqiong Li, Rui Yan, Bi-Cheng Liu
Summary: This study evaluated the safety, pharmacokinetics, and efficacy of HSK21542 in hemodialysis patients. It found that HSK21542 was well tolerated within the dose range of 0.05-0.80 μg/kg, and HSK21542-0.3 μg/kg exhibited promising efficacy in patients with moderate to severe pruritus.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Laurent Misery, Emilie Brenaut, Ophelie Pierre, Raphaele Le Garrec, Olivier Gouin, Nicolas Lebonvallet, Claire Abasq-Thomas, Matthieu Talagas, Christelle Le Gall-Ianotto, Catherine Besner-Morin, Joachim W. Fluhr, Cyril Leven
Summary: Until recently, limited understanding and effectiveness in relieving itch were common, but current progress in knowledge of itch processing and therapeutic pathways has led to a variety of compounds being tested in clinical trials, with inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4, or TRP being the main ones. Further exploration into new targets such as Mas-related GPCRs and unexpected pathways is also needed.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Ya-Fei Bai, Chun-Li Wang, Ming-Zhi Xu, Ming-Jiao Pan, Qing-Yi Sun, Ru-Man Chen
Summary: Skin pruritus is a common complication in patients with uremia, impacting their quality of life. Treatments like hemodialysis can help alleviate symptoms, while traditional Chinese medicine UCG combined with HFH shows significant efficacy in treating uremic pruritus.
Article
Medicine, General & Internal
Ichiei Narita, Yoshiharu Tsubakihara, Takuma Uchiyama, Shota Okamura, Nobuyo Oya, Naoki Takahashi, Fumitake Gejyo
Summary: This phase 2 trial suggests that 0.5 pg/kg of difelikefalin is the clinically recommended dose for treating moderate to severe pruritus in hemodialysis patients due to its efficacy, acceptable tolerability, and manageable safety profile.
Editorial Material
Dermatology
Kelsey L. Auyeung, Blair A. Jenkins, Brian S. Kim
Summary: This article reviews the underlying mechanisms and treatment methods of peripheral sensory itch conditions.
Review
Neurosciences
Brian S. Kirri
Summary: This article introduces the importance of itch sensation for survival and its value in the field of medicine, highlighting how research in itch biology has led to important discoveries and breakthroughs in treatment.
Article
Medicine, General & Internal
Laurent Misery
Summary: Pain can be classified into nociceptive pain, neuropathic pain, and nociplastic pain; similarly, itch can be classified into pruriplastic pruritus. Proper classification of pain and itch can help in better treating chronic pain and itch.
FRONTIERS IN MEDICINE
(2021)
Article
Neurosciences
Manuel Pedro Pereira, Martin Schmelz, Sonja Staender
Summary: Neuropathic pruritus conditions result from damage to the nervous system, and novel findings strengthen the specificity theory of pruritus transmission. Activation of nociceptors and specific discharge patterns of primary afferents also contribute to itch development. Interactions between excitatory and inhibitory interneurons, non-neuronal cells, and descending modulation from upper centers contribute to neuronal sensitization, leading to chronic itch and accompanying phenomena.
CURRENT OPINION IN NEUROBIOLOGY
(2022)